Skip to content

Study on mechanism of effect of drug metabolic system on clinical precision drug use in high-fat population based on transcriptome technology

Study on mechanism of effect of drug metabolic system on clinical precision drug use in high-fat population based on transcriptome technology

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041714
Enrollment
Unknown
Registered
2021-01-02
Start date
2021-01-15
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia?Fatty liver

Interventions

hyperlipidemia group and non-hyperlipidemia group:Nil

Sponsors

Zunyi Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years old, sex is not limited; 2. According to the Guidelines for primary diagnosis and treatment of dyslipidemia (2019), the selection criteria of Hyperlipidemia Group were defined as: (1) Total cholesterol (TC)>= 6.2 mmol/l; (2) Low-density lipoprotein cholesterol (LDL-C) >= 4.1 mmol/l; (3) Triglyceride cholesterol =2.3 mmol/l; (4) High-density lipoprotein (HDL-C) = 7.0 mmol/l; (2) Glycated hemoglobin >= 6.5(%) ; (3) total cholesterol (TC) >= 6.2 mmol/l; (4) Low-density lipoprotein cholesterol (LDL-C)>= 4.1 mmol/l; (5) triglyceride >= 2.3 mmol/l; (6) high-density lipoprotein (HDL-C) < 1.0 mmol/L. The inclusion criteria of non-fatty liver included: no steatosis, fasting blood glucose (3.9-6.1 mmol/L) , total cholesterol (TC) < 5.2 mmol/l, Low-density lipoprotein (LDL-C) < 3.12 mmol/l, triglyceride < 1.70 mmol/L, and high-density lipoprotein (HDL-C)0.91-1.55 mmol/L. 4. voluntary and signed Pic.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Hyperlipidemia and homozygous hypercholesterolemia caused by drugs (phenothiazines, beta-blockers, adrenal cortex steroids and some contraceptives); 3. Alcoholic fatty liver disease.

Design outcomes

Primary

MeasureTime frame
RNA;

Countries

China

Contacts

Public ContactYuhe Wang

Zunyi Medical University Hospital

1149076068@qq.com+86 15186696789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026